[Federal Register Volume 78, Number 161 (Tuesday, August 20, 2013)]
[Notices]
[Page 51210]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-20259]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Chattem Chemicals, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 21, 2013, Chattem 
Chemicals, Inc., 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                             Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010).............................          I
4-Methoxyamphetamine (7411)..................................          I
Dihydromorphine (9145).......................................          I
Amphetamine (1100)...........................................         II
Methamphetamine (1105).......................................         II
Lisdexamfetamine (1205)......................................         II
Methylphenidate (1724).......................................         II
Pentobarbital (2270).........................................         II
Codeine (9050)...............................................         II
Dihydrocodeine (9120)........................................         II
Oxycodone (9143).............................................         II
Hydromorphone (9150).........................................         II
Hydrocodone (9193)...........................................         II
Meperidine (9230)............................................         II
Methadone (9250).............................................         II
Methadone intermediate (9254)................................         II
Morphine (9300)..............................................         II
Oripavine (9330).............................................         II
Thebaine (9333)..............................................         II
Opium tincture (9630)........................................         II
Opium, powdered (9639).......................................         II
Opium, granulated (9640).....................................         II
Oxymorphone (9652)...........................................         II
Noroxymorphone (9668)........................................         II
Alfentanil (9737)............................................         II
Remifentanil (9739)..........................................         II
Sufentanil (9740)............................................         II
Tapentadol (9780)............................................         II
Fentanyl (9801)..............................................         II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution and sale to its customers. Regarding (9640) 
the company plans to manufacture another controlled substance for sale 
to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 21, 2013.

    Dated: August 14, 2013.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-20259 Filed 8-19-13; 8:45 am]
BILLING CODE 4410-09-P